Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Control ChangeItem 5.01 · 8-KLOW RiskNeutral

Kairos Pharma Ltd.

Filed: Jun 29, 2026CIK: 001-42275Health Care
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Kairos Pharma Ltd. held its 2026 annual stockholder meeting on June 29, 2026, with 62.81% share participation (13.45M of 21.41M shares). The meeting included voting on five proposals, including director elections, which will influence the company's future governance and strategic direction.

Key Takeaways

Annual meeting held on June 29, 2026 with strong shareholder participation at 62.81% of eligible shares

Five proposals were voted on, including director elections that will shape future company leadership

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 29, 2026
Item5.01
CategoryControl Change
CIK001-42275
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
board change

What This Means

Control of the company has changed. This could be through acquisition, proxy contest, or board restructuring.
View Full Filing on SEC.govBrowse More Filings